Celcuity (CELC) Accumulated Depreciation (2020 - 2025)
Celcuity's (CELC) quarterly Accumulated Depreciation came in at $2.2 million in Q4 2025, up 8.38% YoY from $2.0 million in Q4 2024, and up 8.38% on a QoQ basis from $2.0 million in Q4 2024.
Celcuity (CELC) Accumulated Depreciation (2020 - 2025) Analysis & Trends
Celcuity (CELC) has 6 years of Accumulated Depreciation data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Accumulated Depreciation rose 8.38% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 8.38% YoY) and the FY2025 annual result came in at $2.2 million, up 8.38% from the prior year.
- Accumulated Depreciation climbed to $2.2 million in Q4 2025, from $2.0 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $2.2 million in Q4 2025 to a low of $1.5 million in Q4 2021.
- A 5-year average of $1.8 million and a median of $1.9 million in 2023 frame the typical range for Accumulated Depreciation.
- Annual changes were most pronounced in 2021 — Accumulated Depreciation rose 25.12% — and 2024, when it increased 6.98%.
- Tracing CELC's Accumulated Depreciation over 5 years: stood at $1.5 million in 2021, then grew by 13.98% to $1.7 million in 2022, then increased by 8.3% to $1.9 million in 2023, then climbed by 6.98% to $2.0 million in 2024, then gained by 8.38% to $2.2 million in 2025.
- The last three Accumulated Depreciation figures came in at $2.2 million (Q4 2025), $2.0 million (Q4 2024), and $1.9 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.16 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Dec 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 1.51 Mn |
| Dec 31, 2020 | 1.21 Mn |